AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...